Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses treatment approaches for midrange ejection fraction heart failure with reduced ejection fraction (HFrEF). Albert notes there is no single approach; it depends on the individual patient. However, evidence supports, in some patients, starting all 4 pillar medications (angiotensin receptor-neprilysin inhibitors [ARNIs], angiotensin-converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]; evidence-based beta blockers [metoprolol succinate, bisoprolol, carvedilol]; mineralocorticoid receptor antagonists [MRAs; spironolactone, eplerenone]; and sodium-glucose cotransporter-2 [SGLT2] inhibitors [dapagliflozin, empagliflozin]) within 2 weeks and optimizing doses within 1 month. Monitoring kidney function, potassium, and sodium guides safe intensification. The approach should be urgent, avoiding a “stable” mindset. Desai emphasizes the mortality benefits of quadruple therapy in HFrEF, yet real-world data shows only 1% of heart failure (HF) patients receive guideline-directed triple therapy. Like cancer, HF requires rapid multidrug therapy, not an incremental “start low, go slow” approach. The stakes are high to close evidence-practice gaps. Axsom draws an analogy to cancer and HF both being chronic life-threatening diseases demanding rapid treatment. Wright notes the multidirectional relationship between conditions like HF, kidney disease, and diabetes, requiring combined management.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More